Individuals thinking about participating in cancer clinical trials to help discover tomorrow's treatments deserve advertising messages that are truthful, balanced, and respectful of their role in advancing science, not hype.
chadi nabhan MD, MBAJust listened to this #AACR18 debate & I believe @DHymanMD & @VinayPrasadMD agree more than disagree. Didn’t get a chance to hear what the moderator said after. BUT, saying trials r unethical by @DHymanMD is a big mistake. You can listen here
BackgroundThe majority of patients with metastatic melanoma obtain only short-term or no benefit at all from checkpoint inhibitor (CPI) immunotherapy. In this study, we investigated whether the immune system of patients progressing following CPI...
FabriceAndreMD🔥🔥🔥TILs are still responsive to autologous tumor AFTER resistance to IO. this could explain why the post-PD OS is longer in patients pretreated with IO ?? analysis of post PD TILs will certainly inform about outcome and further sensitivity to IO
Providing access to patients has to go beyond the traditional hospital and clinic setting. Enlisting the community centers and leaders in which people trust and earning their trust as expert health care providers is an invaluable combination.
AstraZeneca has found another trap door for its combination of the PD-L1 checkpoint Imfinzi and its CTLA-4 combination drug tremelimumab. The research team on ARCTIC says the combo has failed on both progression-free survival as well as overall...
H. Jack West, MDDisappointing that a PD-L1/CTLA-4 IO combination failed to exceed low bar of std of care 3rd line in adv NSCLC. Should only further lower our expectations about MYSTIC. AstraZeneca’s durvalumab/tremelimumab combo fizzles again on lung cancer bit.ly/2JmJvJu #LCSM
• Cytokine release syndrome often occurs immediately after haploidentical transplant.•
Post-transplant cyclophosphamide-based Graft-versus-Host Disease prophylaxis facilitates
resolution of CRS.• Peripheral blood grafts significantly increase the...
Mehdi HamadaniCytokine Release Syndrome more common after RIC peripheral Blood HaploHCT. Likely NOT inconsequential (probably increases NRM/aGvHD).
Need larger studies on this. @renjuvraj@SChhabra_MCW #MCWBMT-Team
This Viewpoint uses the recent instance of disease awareness promotion on a television soap opera to discuss questions about the role and regulation of novel forms of direct-to-consumer disease awareness marketing.
To the Editor The rise of machine learning is changing diagnostic medicine. Dr Ehteshami Bejnordi and colleagues reported the researcher challenge competition (CAMELYON16)1 comparing diagnostic performance between deep learning algorithms and expert...